Clinical Trial Detail

NCT ID NCT02144038
Title Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

multiple myeloma

Therapies

Alpelisib + LGH447

LGH447

Age Groups: adult

No variant requirements are available.